Evidence map›Paper›PMID 41964090›Full record

ArticleJournal of experimental & clinical cancer research : CR2026

The aryl hydrocarbon receptor, CIITA and HLA-II: who is watching the watchdog?

Doriana Fruci, Patrizio Giacomini

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Doriana FruciDepartment of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy. doriana.fruci@opbg.net.
Patrizio GiacominiUOSD Medicina di Precisione in Senologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli, 8, Rome, 00168, Italy. patrizio.giacomini@guest.policlinicogemelli.it.

Funding

Fondazione AIRC per la ricerca sul cancro ETS IG24345
6 · The paper itself

Abstract

backgroundA recent paper by Jin et al. reveals an unexpected role of the Aryl Hydrocarbon Receptor (AHR), so far considered an environmental sensor. The authors demonstrate that AHR transactivates CIITA, thereby up-regulating antigen-presenting HLA-II molecules in cutaneous melanoma. MAIN BODY: In this commentary, we review the evidence supporting this original observation and discuss its potential biological implications.

conclusionsThese findings suggest that the environmental exposome and HLA-II-mediated antigen presentation should be considered interconnected aspects of self-non-self-discrimination, with potentially important implications for tumor (immune) surveillance.

Indexed as

Histocompatibility Antigens Class IIMelanomaNuclear ProteinsReceptors, Aryl HydrocarbonTrans-ActivatorsAntigen PresentationHumansHistocompatibility Antigens Class IIMHC class II transactivator proteinNuclear ProteinsReceptors, Aryl HydrocarbonTrans-ActivatorsAntigen presentationAryl Hydrocarbon ReceptorCIITAEnvironmental sensingHLA class II

Identifiers

PMID41964090
PMCPMC13067543

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.